Provided by Tiger Trade Technology Pte. Ltd.

HUTCHMED

19.830
0.000
Volume:4.21M
Turnover:83.64M
Market Cap:17.29B
PE:4.86
High:20.040
Open:19.840
Low:19.580
Close:19.830
52wk High:28.800
52wk Low:15.570
Shares:872.00M
HK Float Shares:872.00M
Volume Ratio:0.94
T/O Rate:0.48%
Dividend:- -
Dividend Rate:- -
EPS(LYR):4.077
ROE:1.46%
ROA:-1.24%
PB:1.75
PE(LYR):4.86
PS:4.02

Loading ...

HK Movers | Pharma Stocks Gain With HUTCHMED up 8%, JOINN up 6%

Tiger Newspress
·
Aug 17

HUTCHMED: ORPATHYS®-TAGRISSO® Combo Delivers Significant PFS and OS Gains in Global Phase III SAFFRON Study for MET-Driven EGFR-Mutant NSCLC

Bulletin Express
·
Aug 17

Hutchmed (China) - Says Orpathys Plus Tagrisso Improves Survival in Egfr-Mutated Nsclc in Phase Iii Trial

THOMSON REUTERS
·
Aug 17

Hutchmed Says Savolitinib Plus AstraZeneca’s Tagrisso Lifts PFS and OS in Phase III Lung Cancer Trial

Reuters
·
Aug 17

Hutchmed Announces Orpathys® Plus Tagrisso® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in Met-Driven Egfr-Mutated Lung Cancer After Progression on Tagrisso®

THOMSON REUTERS
·
Aug 17

HUTCHMED H1 2026: Net Profit at $15.90 Million, Oncology Revenue Climbs 23%, Liquidity Reaches $1.37 Billion

Bulletin Express
·
Aug 14

Hutchmed H1 FY26 Net Income Drops to $15.9 Million; Revenue Rises 0.22% to $278.3 Million

Reuters
·
Aug 14

UBS Adjusts HUTCHMED Target Price to HK$29.5, Maintains Buy Rating

Stock News
·
Aug 03

Hutchmed H1 FY26 Net Income Drops to USD 15.9 Million; Revenue Rises 0.22% to USD 278.3 Million

Reuters
·
Jul 30

HUTCHMED (China) H1 EPS $0.09 Down From $2.61 YoY, Sales $278.287M Up From $277.677M YoY

Benzinga Earnings
·
Jul 30

Hutchmed (China) - Reiterates Fy2026 Guidance for Oncology/Immunology Revenue of $330-$450 Mln

THOMSON REUTERS
·
Jul 30

Hutchmed (China) - Net Income Attributable to Hutchmed at $15.90 Mln in H1 2026

THOMSON REUTERS
·
Jul 30

Hutchmed China Ltd - Hutchmed Reports 2026 Interim Results

THOMSON REUTERS
·
Jul 30

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

GlobeNewswire
·
Jul 07

Hutchmed Gets China Nod for Gastric Cancer Drug Application

MT Newswires Live
·
Jul 02

HUTCHMED's Savolitinib Gains Conditional NMPA Approval for MET-Amplified Gastric Cancer

Stock News
·
Jul 02

Hutchmed Says China Regulator Grants Conditional Approval for Orpathys in Met-amplified Gastric Cancer

Reuters
·
Jul 02

Hutchmed Announces Nmpa Approval for Orpathys® for the Treatment of Gastric Cancer Patients with Met Amplification

THOMSON REUTERS
·
Jul 02

HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification

GlobeNewswire
·
Jul 02

HUTCHMED Sets 30 July Board Meeting to Approve 2026 Interim Results; Webcast Details Announced

Bulletin Express
·
Jun 30